Central nervous system (CNS) metastases remain a major clinical challenge in the management of non–small cell lung cancer (NSCLC), particularly in tum...

Circulating tumor DNA (ctDNA) has promise as a therapeutic monitoring tool, but personalization by patient is important, and there remain challenges a...

New research from Taiwan suggests that the cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 di...

Patients with lower socioeconomic status were less likely to get certain biomarker testing done and had a longer time between their diagnosis and biom...

Medicare Advantage beneficiaries experienced disproportionately greater increases in hospital length of stay after the COVID-19 pandemic than those wi...

The management of advanced non–small cell lung cancer (NSCLC) with EGFR mutations continues to evolve as novel targeted therapies and administration s...

A retrospective, long-term real-world study of 93 patients with psoriasis and psoriatic arthritis (PsA) treated with anti-tumor necrosis factor (TNF)-...

The treatment of non–small cell lung cancer (NSCLC) has changed dramatically in recent years with the rise of biomarker-driven targeted therapies and...

At a recent Institute for Value-Based Medicine® event, Oranus Mohammadi, MD, a medical oncologist and hematologist at The Oncology Institute in Los An...

Biomarker testing is a crucial step for those diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC), but nearly one-third of eligible...